 |
| Lasilactone |
The possible adverse effects of excessive excretion of urine (diuresis) are: Decrease in blood volume (hypovolemia) and sodium depletion (hyponatremia),
dryness of the mouth and thrombophilia, fall in blood pressure sometimes
progressing to circulatory collapse, feeling of weakness and circulatory disturbances
such as dizziness, headaches, visual impairment, drowsiness and calf cramps. A
physician should be consulted in such cases.
In common with other diuretics, the treatment with L may induce a
transient rise in serum creatinine and urea
At the start of treatment a fall in the serum potassium level may occur. Moreover
calcium depletion may be experienced.
Symptoms of obstructed micturition (hydronephrosis, prostatic hypertrophy,
ureterostenosis) may become manifest or may be aggravated under the action of
furosemide.
It should be remembered that an increase in uric acid concentration in the blood
might precipitate attacks of gout in predisposed patients.
Existing diabetes may be aggravated, and latent diabetes may become clinically
manifested.
Isolated cases of acute pancreatitis have been reported, in which the treatment
with saluretics over several weeks was considered a causal factor. Also few cases
of acute pancreatitis have been reported following therapy with furosemide.
Disorders of hearing occurring after furosemide are rare and in-most cases
reversible. This possibility should be borne in mind, especially if furosemide is
injected too rapidly and in particular in patients with renal insufficiency. Ability to Drive and Operate Machinery:
In individual cases, the ability to drive, cross the road safely or operate machinery
may be impaired, especially at the commencement of treatment or when changing
______ over from other drugs, or when alcohol is consumed during therapy. Interactions: ______ In patients under concomitant treatment with potassium-containing or potassium
sparing drugs (potassium chloride, triamterene, amiloride) or with ACE-inhibitors,
there may be an excessive rise in serum potassium levels.
______ Spironolactone may reduce the effect of carbenoxolone (used for treatment of
______ gastrointestinal ulcers).
Salicylates (analgesics) may attenuate the effect of spironolactone.
Furosemide sometimes diminishes the potency of drugs (e.g. antidiabetics and
pressor amines) or potentiate their effect (e.g. salicylates, theophylline, lithium,
and curaremimetic muscle relaxants).
The action of other hypotensive drugs (e.g. ACE-inhibitors, beta-blocking agents)
may be potentiated by Lasilactone. —
Non-Steroidal anti-inflammatory drugs (e.g. indomethacin, acetylsalicylic acid)
may attenuate the action of furosemide.
Furosemide may potentiate the nephrotoxic effects of certain antibiotics (e.g. —
aminoglycosides). Therefore, furosemide should be used with caution in patients
with antibiotic-induced renal impairment. —
It should be borne in mind that the ototoxicity of aminoglycoside antibiotics (e.g.
kanamycin, gentamicin, tobramycin) may be potentiated when furosemide is used
concurrently. The hearing defects that result may be irreversible. Therefore, these
drugs combination should be restricted to vital indications.
In case of concomitant glucocorticoid medication or abuse of laxatives, Lasilactone
may lead topotassium deficiency. In the presence of potassium deficiency the
effect of cardiac glycosides may be enhanced. Dosage: Unless otherwise prescribed, the following dosage guidelines apply for adults:
For the first 3 to 6 days, 1 tablet Lasilactone up to 4 times daily should be
administered, depending on the indication and severity of the condition.
For maintenance treatment, 1 tablet Lasilactone up to 3 times daily is adequate.
This dose may be taken every day, or every 2d or 3’ day, as required. Administration: The tablet should be swallowed whole with a sufficient amount of liquid, preferably
with breakfast or lunch. It is not advisable to take the drug in the evening, especially
at the start of treatment, because of the i:ncreased urine excretion expected.
Duration of treatment is determined by the physician. Expiry Date: Do not use later than the date of expiry indicated.
Keep medicines out of the reach of children Presentation: Packs of 10 film-coated tablets. Produced by sanofi-aventis egypt s.a.e.
Under licence of sanofi-aventis I Germany
dryness of the mouth and thrombophilia, fall in blood pressure sometimes
progressing to circulatory collapse, feeling of weakness and circulatory disturbances
such as dizziness, headaches, visual impairment, drowsiness and calf cramps. A
physician should be consulted in such cases.
In common with other diuretics, the treatment with L may induce a
transient rise in serum creatinine and urea
At the start of treatment a fall in the serum potassium level may occur. Moreover
calcium depletion may be experienced.
Symptoms of obstructed micturition (hydronephrosis, prostatic hypertrophy,
ureterostenosis) may become manifest or may be aggravated under the action of
furosemide.
It should be remembered that an increase in uric acid concentration in the blood
might precipitate attacks of gout in predisposed patients.
Existing diabetes may be aggravated, and latent diabetes may become clinically
manifested.
Isolated cases of acute pancreatitis have been reported, in which the treatment
with saluretics over several weeks was considered a causal factor. Also few cases
of acute pancreatitis have been reported following therapy with furosemide.
Disorders of hearing occurring after furosemide are rare and in-most cases
reversible. This possibility should be borne in mind, especially if furosemide is
injected too rapidly and in particular in patients with renal insufficiency. Ability to Drive and Operate Machinery:
In individual cases, the ability to drive, cross the road safely or operate machinery
may be impaired, especially at the commencement of treatment or when changing
______ over from other drugs, or when alcohol is consumed during therapy. Interactions: ______ In patients under concomitant treatment with potassium-containing or potassium
sparing drugs (potassium chloride, triamterene, amiloride) or with ACE-inhibitors,
there may be an excessive rise in serum potassium levels.
______ Spironolactone may reduce the effect of carbenoxolone (used for treatment of
______ gastrointestinal ulcers).
Salicylates (analgesics) may attenuate the effect of spironolactone.
Furosemide sometimes diminishes the potency of drugs (e.g. antidiabetics and
pressor amines) or potentiate their effect (e.g. salicylates, theophylline, lithium,
and curaremimetic muscle relaxants).
The action of other hypotensive drugs (e.g. ACE-inhibitors, beta-blocking agents)
may be potentiated by Lasilactone. —
Non-Steroidal anti-inflammatory drugs (e.g. indomethacin, acetylsalicylic acid)
may attenuate the action of furosemide.
Furosemide may potentiate the nephrotoxic effects of certain antibiotics (e.g. —
aminoglycosides). Therefore, furosemide should be used with caution in patients
with antibiotic-induced renal impairment. —
It should be borne in mind that the ototoxicity of aminoglycoside antibiotics (e.g.
kanamycin, gentamicin, tobramycin) may be potentiated when furosemide is used
concurrently. The hearing defects that result may be irreversible. Therefore, these
drugs combination should be restricted to vital indications.
In case of concomitant glucocorticoid medication or abuse of laxatives, Lasilactone
may lead topotassium deficiency. In the presence of potassium deficiency the
effect of cardiac glycosides may be enhanced. Dosage: Unless otherwise prescribed, the following dosage guidelines apply for adults:
For the first 3 to 6 days, 1 tablet Lasilactone up to 4 times daily should be
administered, depending on the indication and severity of the condition.
For maintenance treatment, 1 tablet Lasilactone up to 3 times daily is adequate.
This dose may be taken every day, or every 2d or 3’ day, as required. Administration: The tablet should be swallowed whole with a sufficient amount of liquid, preferably
with breakfast or lunch. It is not advisable to take the drug in the evening, especially
at the start of treatment, because of the i:ncreased urine excretion expected.
Duration of treatment is determined by the physician. Expiry Date: Do not use later than the date of expiry indicated.
Keep medicines out of the reach of children Presentation: Packs of 10 film-coated tablets. Produced by sanofi-aventis egypt s.a.e.
Under licence of sanofi-aventis I Germany